Retatrutide in 2026: what the phase 3 numbers mean
Why TRIUMPH-1 reports both 25.0% and 28.3% weight loss, what its safety findings show, and how those results differ from FDA approval.
A place for slower thoughts
Dr. Mike’s Peptide Notes
Peptide science, metabolic medicines, and clinical evidence—clear explanations of what studies show, what formulations change, and where important questions remain.
Words by Michael N.
The archive
7 storiesFrom the notebook
The engineering hidden inside an oral peptide tablet
Oral semaglutide shows how a carefully studied formulation can overcome a delivery barrier—and why that evidence cannot be borrowed by every peptide capsule.
GLP-1 and GIP: reading the semaglutide–tirzepatide comparison
A receptor count cannot rank a medicine. Current US labels and the SURMOUNT-5 trial show why product, population and outcome must stay attached to every comparison.
BPC-157: what the human evidence can actually say
Laboratory findings, a knee-pain series and a two-person safety pilot answer different questions. Follow the evidence before turning a plausible mechanism into a recovery claim.
How to read a peptide trial without losing the plot
A trial number begins an investigation. Use real BPC-157 and SELECT records to separate registration, results, absolute benefits, observed harms and a specific FDA approval.
What a peptide certificate of analysis does and does not prove
A purity percentage answers a defined analytical question. Identity, amount, sterility, endotoxins, clinical benefit and regulatory approval each require their own evidence.
What a peptide is—and what the name cannot tell you
Peptide describes molecular construction. Sequence, targets, formulation and human evidence determine what a particular peptide can actually claim to do.
Meet the writers
All authors